Creating new compounds to understand gut bacteria and fight infections
Chemical synthesis to access rare heterocycles and tool compounds to probe bacterial polysaccharide metabolism
This project creates new chemical compounds to better understand how gut bacteria process sugars and to find new ways to fight parasitic infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clemson University NIH-funded |
| Lab location | 1 site (Clemson, United States) |
| Project ID | NIH-11166337 on NIH RePORTER |
What this research studies
Our bodies rely on a delicate balance of gut bacteria, and this project aims to understand how some of these bacteria, like Bacteroides, interact with the sugars we eat. We are also developing unique chemical compounds that could potentially act as new treatments against parasites. By creating these special molecules, we hope to uncover new ways to support gut health and combat various infections. This work focuses on the very early stages of drug discovery, building the foundational knowledge for future medicines.
Who could benefit from this research
Good fit: This foundational chemistry project does not directly involve patient participation at this stage, but future clinical applications could benefit individuals with parasitic infections or imbalances in gut bacteria.
Not a fit: Patients seeking immediate treatment options or direct clinical intervention will not find direct benefit from this early-stage chemical synthesis project.
Why it matters
Potential benefit: If successful, this work could lead to new types of medications for parasitic infections and a deeper understanding of how gut bacteria influence our health, potentially opening doors for treatments for bacterial and autoimmune conditions.
How similar studies have performed: The development of diazacyclobutene (DCB) heterocycles is a novel approach, with preliminary biological investigations showing potent anti-parasitic activity, suggesting a promising but largely untested direction.
Where this research is happening
Clemson, United States
- Clemson University — Clemson, United States (Active)
Researchers
- Principal investigator: Whitehead, Daniel Charles — Clemson University
- Study coordinator: Whitehead, Daniel Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.